332235

Drug Profile

332235

Alternative Names: SB 332235

Latest Information Update: 01 Dec 2004

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GlaxoSmithKline
  • Class Small molecules
  • Mechanism of Action Interleukin 8 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Chronic obstructive pulmonary disease; Psoriasis

Most Recent Events

  • 01 Dec 2004 Discontinued - Phase-I for Chronic obstructive pulmonary disease in United Kingdom (PO)
  • 01 Dec 2004 Discontinued - Preclinical for Psoriasis in United Kingdom (PO)
  • 12 Oct 2004 Data presented at the 228th American Chemical Society National Meeting (228th-ACS-2004) have been added to the pharmacokinetics and Respiratory Tract Disorders pharmacodynamics sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top